# 3/14 ApoL1 Long-Term Kidney Transplantation Outcomes Network (Apollo) Clinical Center

> **NIH NIH U01** · JOHNS HOPKINS UNIVERSITY · 2024 · $246,000

## Abstract

Project Summary
Genetic variants in APOL1 commonly found in people of Western Sub-Saharan Africa ancestry
are associated with kidney diseases such as Focal Segmental Glomerulosclerosis, Hypertension
Attributed-End Stage Kidney Disease, and HIV-Associated Nephropathy. The presence of 2
APOL1- renal risk variants (RRV) in deceased donors is associated with 2-to-4-times higher risk
of renal graft loss in the recipient. Living donors with APOL1 risk alleles may be at risk for kidney
disease. The NIH established the “APOL1 Long-term Kidney Transplantation Outcomes”
(APOLLO) U01 Consortium in 2017. The APOLLO Consortium includes 13 clinical centers
(CCs) with 4 paired core Centers to study the role of APOL1. The Johns Hopkins/Saint Louis
University CC is CC3. The primary objectives of the APOLLO Consortium are to assess
outcomes in patients across the entire United States who receive a kidney from an AA donor, or
other individuals with recent African ancestry, and to evaluate the association of APOL1 genotype
with renal allograft function-related outcomes. The primary outcome is time to graft failure in the
recipients. Other outcomes include the rate of change of kidney function in recipients, rates of
acute rejection of the kidney transplant, and proteinuria. The APOLLO Consortium also ascertains
meaningful longitudinal outcomes in AA living donors (LDs), focusing on vital status and renal
function, as well as proteinuria. While APOLLO enrolls LDs, their relative numbers have been
limited, highlighting the need for additional studies designed to more thoroughly define the
relationships of APOL1 genotype with long-term LD outcomes This application seeks to build on
and extend the findings of the APOLLO study to inform clinical practice by a) providing data
regarding the effects of APOL1 genotype on outcomes of the recipients of kidneys from AA
donors, b) providing data regarding the effects of APOL1 genotype on long-term survival and
renal functional outcomes of AA LDs and their recipients, and c) establishing a resource of clinical
and genetic data and biological specimens for the APOLLO Consortium and other future
researchers through the NIDDK Central Repository.

## Key facts

- **NIH application ID:** 10917299
- **Project number:** 5U01DK116042-08
- **Recipient organization:** JOHNS HOPKINS UNIVERSITY
- **Principal Investigator:** Daniel Conlon Brennan
- **Activity code:** U01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $246,000
- **Award type:** 5
- **Project period:** 2017-09-25 → 2028-05-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10917299

## Citation

> US National Institutes of Health, RePORTER application 10917299, 3/14 ApoL1 Long-Term Kidney Transplantation Outcomes Network (Apollo) Clinical Center (5U01DK116042-08). Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/grant/nih/10917299. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*